Skip to content
Friday 7 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,901.09
+0.31%
DAX
26,319.45
+0.69%
CAC 40
8,714.93
+0.17%
STOXX 50
6,523.86
+0.33%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

Pfizer

  • Regulator wins decade-long pricing tussle with Pfizer

    Legal

    The UK competition watchdog has won permission to appeal in a case against US pharmaceutical giant Pfizer after a long-running legal battle over allegations of excessive pricing, overturning a previous decision by the Tribunal. The court said the Competition Appeal Tribunal (CAT), was “wrong to set aside the [Competition and Market’s Authority’s] decision” in relation to [...]

    Hikma reported a jump in profit for 2024
  • GSK to acquire US biotech group for $2.2bn

    Business

    FTSE 100 giant GSK has reached an agreement to acquire US based biotech group Rapt Therapeutics. The deal values the company, which develops therapies for treating people with inflammatory and immunologic diseases, at $2.2bn (£1.6bn), and marks the first major deal for new GSK chief executive Luke Miels, coming just weeks after he took charge [...]

    GSK logo displayed prominently, signifying the companys presence and relevance in the business and healthcare sectors.
  • European court sides with NYT over requests for von der Leyen’s texts with Pfizer CEO

    Legal

    European Court of Justice found that the Commission failed to explain why text messages with Pfizer should be kept from the public

    The far-right Patriots for Europe has ongoing rows over its funding
  • As FTSE 100 pharma firms wait for a tariffs decision, what would drugs levies mean for consumers?

    April 22, 2025

    For FTSE 100 businesses navigating the shifting sands of Trump’s trade war, the uncertainty surrounding the tariffs has been almost as painful as the stock market shocks.  The pharmaceutical industry has been left in a particularly agonising limbo: free, for now, from the 10 per cent baseline import tax, but the US President keeps making [...]

  • GSK shares rise after £1.7bn Zantac settlement

    October 10, 2024

    GSK shares have spiked today after the pharmaceutical giant agreed to pay as much as $2.2bn (£1.68bn) to settle lawsuits alleging one of its heartburn drugs had caused cancer. The discontinued version of the drug, Zantac, had triggered 80,000 lawsuits from 10 different law firms in the US and has hung over the FTSE 100 [...]

  • Pharma giants GSK, Pfizer and Sanofi granted supreme court hearing in Zantac cancer lawsuits

    August 28, 2024

    Delaware’s top court is set to hear an appeal from GSK and other pharmaceutical giants to throw out over 70,000 lawsuits alleging that the now-discontinued heartburn drug Zantac caused cancer. The companies, which also include Pfizer and Sanofi, are challenging a lower court ruling that allowed expert testimony claiming Zantac causes cancer – a link [...]

  • GSK wins latest Zantac trial as jury finds drug did not cause woman’s cancer

    August 6, 2024

    GSK - formerly GlaxoSmithKline - has won its latest trial over whether its most popular drug caused cancer on Monday, after a jury found it was not the root cause of an American woman's illness.

  • US drug giant Pfizer beats GSK to UK government contract for 4.9m vaccine shots

    June 25, 2024

    Pfizer has beaten GSK to win a contract to supply millions of doses of a new respiratory vaccine in the UK after the government snubbed the local drugmaker.

  • GSK shares drag the FTSE 100 as company faces muli-billion pound bill after Zantac trial ruling

    June 3, 2024

    GSK has hit back against a US ruling that found it could be sued over the potential cancer-causing properties of its heartburn drug Zantac.

  • GSK: How much could the Zantac lawsuits cost?

    June 3, 2024

    Last month, Shore Capital analysts estimated that up to $30bn (£24bn) for litigation was already priced into GSK’s shares.

Posts pagination

  • Page 1
  • Page 2
  • Next

Trending Articles

  • Revolut founder’s wealth set to balloon amid talks of share award at $500bn valuation

  • Rupert Lowe axes pensions triple lock and pledges tax cuts in economic plan

  • WPP slashes jobs as revenue continues to fall

  • Liverpool owners tipped to sell – but not to Amazon boss Bezos – by former CEO

  • As it happened: Stocks rise as oil fluctuates after Red Sea attack; US-Iran deal ‘being circulated’

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook